Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach

By September 1, 2021, SARS-CoV-2, a respiratory virus that prompted Coronavirus Disease in 2019, had infected approximately 218,567,442 patients and claimed 4,534,151 lives. There are currently no specific treatments available for this lethal virus, although several drugs, including remdesivir and h...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahabadi, Nahid, Zendehcheshm, Saba, Mahdavi, Mohammad, Khademi, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455240/
https://www.ncbi.nlm.nih.gov/pubmed/34568544
http://dx.doi.org/10.1016/j.imu.2021.100745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455240/
https://www.ncbi.nlm.nih.gov/pubmed/34568544
http://dx.doi.org/10.1016/j.imu.2021.100745

Ejemplares similares